TCR T-cell therapy (Cullinan oncology/Fred Hutchinson Cancer Research)

N/A

Report date: 2025/03/20 09:41:27

Base Information

Drug NameTCR T-cell therapy (Cullinan oncology/Fred Hutchinson Cancer Research)
Drug Alias NameJade
ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunostimulantsT lymphocytes stimulants
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCullinan Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCullinan Therapeutics IncFred Hutchinson Cancer Research Center
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A